Author:
Barone Carlo,Landriscina Matteo,Cassano Alessandra
Reference50 articles.
1. André, T., Louvet, C., Maindrault-Goebel, F., Couteau, C., Mabro, M., Lotz, J.P., Gilles-Amar, V., Krulik, M., Carola, E., Izrael, V., and de Gramont, A. 1999. CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR. Eur. J. Cancer
35: 1343–1347.
2. André, T., Boni, C., Mounedji-Boudiaf, L., Navarro, M., Tabernero, J., Hickish, T., Topham, C., Zaninelli, M., Clingan, P., Bridgewater, J., Tabah-Fisch, I., and de Gramont, A., Multicenter International Study of Oxaliplatin/5-Fluorouracil/ Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. 2004. Oxaliplatin, fluorouracil, and leucovorin as adju vant treatment for colon cancer. N. Engl. J. Med.
350: 2343–2351.
3. Aschele, C., Baldo, C., Sobrero, A.F., Debernardis, D., Bornmann, W.G., and Bertino, J.R. 1998. Schedule-dependent synergism between ralti-trexed and irinotecan in human colon cancer cells in vitro. Clin. Cancer Res.
4: 1323–1330.
4. Barone, C., Landriscina, M., Quirino, M., Basso, M., Pozzo, C., Schinzari, G., Di Leonardo, G., D'Argento, E., Trigila, N., and Cassano, A. 2007. Schedule-dependent activity of 5-fluorou-racil and irinotecan combination in the treatment of human colorectal cancer: in vitro evidence and a phase I dose-escalating clinical trial. Br. J. Cancer
96: 21–28.
5. Ciaparrone, M., Quirino, M., Schinzari, G., Zannoni, G., Corsi, D.C., Vecchio, F.M., Cassano, A., La Torre, G., and Barone, C. 2006. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil. Oncology
70: 366–377.